

**Announcement No. 04/2014
2 May 2014****Coloplast makes provision of DKK 1bn for litigation in the USA**

Today Coloplast has decided to make a provision of DKK 1bn to cover potential settlements and other costs in connection with litigation in the USA. The provision amounts to DKK 755m after tax.

In addition to the provision, Coloplast has a product liability insurance of DKK 500m, which brings the total expected costs in connection with litigation in the USA to around DKK 1.5bn.

Since 2011, Coloplast has been named as a defendant in individual lawsuits in various federal and state courts around the United States, alleging injury resulting from use of transvaginal surgical mesh products designed to treat pelvic organ prolapsed and stress urinary incontinence. Coloplast expects around 7,000 legal claims against the company.

Coloplast releases the interim financial report covering Q2 2013/14 on the 7 May 2014 where the above will be included in the financial guidance for the full year of 2013/14.

Lene Skole
CFO

For further information, please contact

Investors and analysts

Lene Skole
Executive Vice President, CFO
Tel. +45 4911 1700

Ian S.E. Christensen
Vice President, Investor Relations
Tel. +45 4911 1800/+45 4911 1301
Email: dkisec@coloplast.com

Nick Fridberg
Sr. Investor Relations Manager
Tel. +45 4911 1800/+45 4911 1456
Email: dknf@coloplast.com

Press and the media

Ulla Lundhus
Head of Media and Positioning
Tel. +45 4911 1929
Email: dkul@coloplast.com

Simon Mehl Augustesen
Media Manager
Tlf. 4911 3488
Email: dksia@coloplast.com

This announcement is available in a Danish and an English-language version.
In the event of discrepancies, the Danish version shall prevail.

The Coloplast logo is a registered trademark of Coloplast A/S. © 2014-05 All rights reserved Coloplast A/S, 3050 Humlebæk, Denmark.

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. We call this intimate healthcare.

Our business includes Ostomy Care, Urology Care, Continence Care and Wound and Skin Care. We operate globally and employ more than 8,500 people.